Research-Grade Peptide
CJC-1295 (with DAC)
A GHRH analogue with Drug Affinity Complex for extended half-life, studied in growth-hormone-release research.
10 in stock
- ✓ ≥ 99% purity by HPLC
- ✓ Third-party tested in Canada, COA on every batch
- ✓ Discreet, tracked shipping · free over $250
A GHRH analogue with Drug Affinity Complex for extended half-life, studied in growth-hormone-release research.
Further reading: CJC-1295 (with DAC) on The Peptide Guide — an independent Canadian reference with compound profiles and a reconstitution calculator. Educational only; nothing there is a statement about this product.
Research background
CJC-1295 with DAC is a modified analogue of growth-hormone-releasing hormone. The Drug Affinity Complex is a chemical modification that binds the peptide to serum albumin, extending its circulating half-life from minutes to days in models. That extended half-life is the entire point of the modification, and the primary distinction from the DAC-free form. Research examines GHRH-receptor signalling and growth-hormone-release patterns in preclinical models, often comparing pulsatile against sustained exposure. Evidence is preclinical. Research Use Only. Not for human or veterinary use.
Supplied as a lyophilised powder for laboratory research use only. Any context described above refers to published preclinical or in-vitro research — not to human or veterinary use.